M100907 attenuates elevated grooming behavior in the BTBR mouse

Behavioural Brain Research

Volumn 313, Issue , 2016, Pages 67-70

  Amodeo, Dionisio A ^a   Rivera, Elaine ^b   Dunn, Jeffrey T ^b   Ragozzino, Michael E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5HT2A receptors; Autism; BTBR mice; Grooming behavior

Indexed keywords

SEROTONIN 2A ANTAGONIST; VOLINANSERIN; FLUOROBENZENE; PIPERIDINE DERIVATIVE; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; AUTISM; BTBR MOUSE; C57BL 6 MOUSE; COMPULSION; CONTROLLED STUDY; GROOMING; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RESTRICTED INTERESTS AND REPETITIVE BEHAVIOR; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; INBRED MOUSE STRAIN; MOTOR ACTIVITY; PSYCHOLOGY; STEREOTYPY;

ANIMALS; AUTISM SPECTRUM DISORDER; FLUOROBENZENES; GROOMING; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MOTOR ACTIVITY; PIPERIDINES; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 84978289248     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.06.064     Document Type: Article

References (25)

1. [1] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5. 2013, American Psychiatric Pub.
2. [2] Kanner, L., Autistic disturbances of affective contact. Nerv. Child 2 (1943), 217–250.
3. [3] Boyd, B.A., McDonough, S.G., Rupp, B., Khan, F., Bodfish, J.W., Effects of a family-implemented treatment on the repetitive behaviors of children with autism?. J. Autism Dev. Disord. 41:10 (2011), 1330–1341.
4. [4] Szatmari, P., Georgiades, S., Bryson, S., Zwaigenbaum, L., Roberts, W., Mahoney, W., Goldberg, J., Tuff, L., Investigating the structure of the restricted, repetitive behaviours and interests domain of autism. J. Child Psychol. Psychiatry 47:6 (2006), 582–590.
5. [5] Farmer, C., Thurm, A., Grant, P., Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs 73:4 (2013), 303–314.
6. [6] Bishop, S.L., Richler, J., Cain, A.C., Lord, C., Predictors of perceived negative impact in mothers of children with autism spectrum disorder. Am. J. Ment. Retard. 112:6 (2007), 450–461.
7. [7] Howlin, P., Goode, S., Hutton, J., Rutter, M., Adult outcome for children with autism. J. Child Psychol. Psychiatry 45 (2004), 212–229.
8. [8] Coutinho, A.M., Oliveira, G., Morgadinho, T., Fesel, C., Macedo, T.R., Bento, C., Marques, C., Ataíde, A., Miguel, T., Borges, L., Vicente, A.M., Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol. Psychiatry 9:3 (2004), 264–271.
9. [9] Sutcliffe, J.S., Delahanty, R.J., Prasad, H.C., McCauley, J.L., Han, Q., Jiang, L., Li, C., Folstein, S.E., Blakely, R.D., Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am. J. Hum. Genet. 77:2 (2005), 265–279.
10. [10] Veenstra-VanderWeele, J., Muller, C.L., Iwamoto, H., Sauer, J.E., Owens, W.A., Shah, C.R., Cohen, J., Mannangatti, P., Jessen, T., Thompson, B.J., Ye, R., Kerr, T.M., Carneiro, A.M., Crawley, J.N., Sanders-Bush, E., McMahon, D.G., Ramamoorthy, S., Daws, L.C., Sutcliffe, J.S., Blakely, R.D., Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc. Natl. Acad. Sci. 109:14 (2012), 5469–5474.
11. [11] Amodeo, D.A., Jones, J.H., Sweeney, J.A., Ragozzino, M.E., Risperidone and the 5‐HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T+ tf/J mice. Autism Res. 7:5 (2014), 555–567.
12. [12] Amodeo, D.A., Jones, J.H., Sweeney, J.A., Ragozzino, M.E., Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors. Behav. Brain Res. 227:1 (2012), 64–72.
13. [13] Silverman, J.L., Tolu, S.S., Barkan, C.L., Crawley, J.N., Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35:4 (2010), 976–989.
14. [14] Kalueff, A.V., Stewart, A.M., Song, C., Berridge, K.C., Graybiel, A.M., Fentress, J.C., Neurobiology of rodent self-grooming and its value for translational neuroscience. Nat. Rev. Neurosci. 17:1 (2016), 45–59.
15. [15] Kas, M.J., Glennon, J.C., Buitelaar, J., Ey, E., Biemans, B., Crawley, J., Ring, R.H., Lajonchere, C., Esclassan, F., Talpos, J., Noldus, L.P., Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology 231:6 (2014), 1125–1146.
16. [16] D'Cruz, A.M., Ragozzino, M.E., Mosconi, M.W., Shrestha, S., Cook, E.H., Sweeney, J.A., Reduced behavioral flexibility in autism spectrum disorders. Neuropsychology, 27(2), 2013, 152.
17. [17] Halberstadt, A.L., Powell, S.B., Geyer, M.A., Role of the 5-HT 2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology 70 (2013), 218–227.
18. [18] Mocci, G., Jiménez-Sánchez, L., Adell, A., Cortés, R., Artigas, F., Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology 79 (2014), 49–58.
19. [19] Langen, M., Bos, D., Noordermeer, S.D., Nederveen, H., van Engeland, H., Durston, S., Changes in the development of striatum are involved in repetitive behavior in autism?. Biol. Psychiatry 76:5 (2014), 405–411.
20. [20] Ellegood, J., Anagnostou, E., Babineau, B.A., Crawley, J.N., Lin, L., Genestine, M., DiCicco-Bloom, E., Lai, J.K., Foster, J.A., Peñagarikano, O., Geschwind, D.H., Pacey, L.K., Hampson, D.R., Laliberté, C.L., Mills, A.A., Tam, E., Osborne, L.R., Kouser, M., Espinosa-Becerra, F., Xuan, Z., Powell, C.M., Raznahan, A., Robins, D.M., Nakai, N., Nakatani, J., Takumi, T., van Eede, M.C., Kerr, T.M., Muller, C., Blakely, R.D., Veenstra-VanderWeele, J., Henkelman, R.M., Lerch, J.P., Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity?. Mol. Psychiatry 20:1 (2015), 118–125.
21. [21] Politte, L.C., McDougle, C.J., Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharm 231 (2014), 1023–1036.
22. [22] McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 162 (2005), 1142–1148.
23. [23] Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling, R.L., Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry 159 (2002), 1337–1346.
24. [24] Hrdlicka, M., Dudova, I., Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatr. Dis. Treat., 11, 2015, 907.
25. [25] Talvik-Lotfi, M., Nyberg, S., Nordström, A.L., Ito, H., Halldin, C., Brunner, F., Farde, L., High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharm 148:4 (2000), 400–403.